What is Antifibrinolytic Drugs Market?
Antifibrinolytic drugs are medicines that promote blood clotting by preventing or slowing down a process called fibrinolysis, which is the breakdown of blood clots. It is used for treatment for hemophilia, in surgical procedures to prevent excessive blood loss, and for heavy menstrual bleeding. The commonly used United States Food and Drugs Administration (FDA)-approved antifibrinolytics include tranexamic acid, aprotinin, and aminocaproic acid.
The market study is being classified and major geographies with country level break-up.
Akorn Inc. (United States), Amerigen Pharmaceuticals Ltd (United States), Xanodyne Pharmaceuticals Inc (United States), Aurobindo Pharma Ltd. (India), Mylan N.V. (United States), Pfizer Inc. (United States), Sanofi S.A. (France), Cadila Healthcare (India) and Takeda Pharmaceutical Company (Japan) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Aurobindo Pharma Ltd. (India), Xanodyne Pharmaceuticals Inc (United States) and ACIC Pharmaceuticals Inc. (Canada).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Antifibrinolytic Drugs market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Antifibrinolytic Drugs market by Type, Application and Region.
On the basis of geography, the market of Antifibrinolytic Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased in Incidence of Angioedema
- Increased Number of Road Accidents
- Rise in the Medical Surgeries
- Increased Research and Development Activities
- High Cost of the Antifibrinolytic Drugs
- Growth in the Geriatric Population
- Growing Healthcare Industry Worldwide
- Stringent Government Rules and Regulations
Market Leaders and some development strategies
In March 2019, Aurobindo Pharma through its subsidiary Acrotech Biopharma LLC has completed the acquisition of a portfolio of seven marketed oncology injectable products, intellectual property and commercial infrastructure from Spectrum Pharmaceuticals Inc.
In January 2020, ANI acquires the 23 generic products from Amerigen to expand its commercial offering in the United States.
Key Target AudienceAntifibrinolytic Drugs Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase